IL6 and COVID-19: Metformin has been proposed to reduce levels of IL-10, IL-6, and TNFα—important mediators in macrophage activation and cytokine release; improves neutrophil/lymphocyte ratio; stabilizes mast cells; decreases thrombosis; and improves endothelial function, thus reducing the adverse impacts of mortality and complication in patients with COVID-19 [13, 22–27].